Suppr超能文献

一名精神分裂症患者从秘密、非自愿口服药物成功过渡到自愿长效注射抗精神病药物治疗:来自日本的病例报告

Successful Transition From Covert, Involuntary Oral Medication to Consensual, Long-Acting, Injectable Antipsychotic Therapy in a Patient With Schizophrenia: A Case Report From Japan.

作者信息

Oguchi Yoshiyo, Miyake Nobumi

机构信息

Department of Neuropsychiatry, St. Marianna University School of Medicine, Kanagawa, JPN.

Department of Neuropsychiatry, Kawasaki Tama Municipal Hospital, Kawasaki, JPN.

出版信息

Cureus. 2025 Sep 9;17(9):e91904. doi: 10.7759/cureus.91904. eCollection 2025 Sep.

Abstract

Medication non-adherence is a primary obstacle in schizophrenia management, often leading to the involuntary or covert administration of medication by caregivers. Covert medication, the practice of administering medicine to a person without their knowledge, occurs in Japan within a complex ethical and legal landscape that lacks clear institutional frameworks, posing significant dilemmas for patients, their families, and clinicians. This report describes a case of a successful transition from such treatment to consensual, patient-centered therapy using long-acting injectable (LAI) antipsychotics. A 57-year-old Japanese man with a long history of schizophrenia experienced repeated relapses due to poor adherence to medication. For three months, his aged father covertly administered oral risperidone. This ethically unsustainable situation prompted a therapeutic shift. After engaging in shared decision-making focused on the patient's personal recovery goals, such as improving computer skills and living more independently, he consented to therapy with paliperidone palmitate LAI. The transition to LAI therapy resulted in marked clinical and functional improvements, evidenced by improved scores across all domains of the Brief Evaluation of Psychosis Symptom Domains and a significant increase in his Global Assessment of Functioning score. The patient resumed household tasks, participated in community activities, and expressed aspirations for the future, leading to dramatic improvements in quality of life and a substantial reduction in caregiver burden. This case highlights how LAIs can serve as a vital tool to resolve the ethical challenges of covert medication, respect patient autonomy, and align with principles of personal recovery. LAI antipsychotics offer an effective and ethically sound alternative to covert medication in schizophrenia. This approach can strengthen the therapeutic alliance, enhance patient autonomy, and lead to meaningful improvements in clinical symptoms and real-world functioning, providing a valuable solution within challenging sociocultural contexts.

摘要

药物治疗依从性不佳是精神分裂症管理中的主要障碍,常常导致照料者非自愿或秘密给药。秘密给药,即在患者不知情的情况下给其用药的做法,在日本发生于一个缺乏明确制度框架的复杂伦理和法律环境中,给患者、其家人及临床医生带来了重大困境。本报告描述了一例成功从这种治疗方式转变为使用长效注射用(LAI)抗精神病药物进行的基于患者同意的、以患者为中心的治疗的案例。一名患有精神分裂症多年的57岁日本男性,因药物治疗依从性差而多次复发。三个月来,他年迈的父亲一直秘密给他口服利培酮。这种在伦理上不可持续的情况促使了治疗方式的转变。在围绕患者的个人康复目标(如提高计算机技能和更独立地生活)进行共同决策后,他同意接受棕榈酸帕利哌酮长效注射剂治疗。向长效注射剂治疗的转变带来了显著的临床和功能改善,《精神病症状领域简要评估》所有领域的得分提高以及其功能总体评估得分显著增加证明了这一点。患者恢复了家务劳动,参与社区活动,并表达了对未来的期望,生活质量得到显著改善,照料者负担大幅减轻。该案例凸显了长效注射剂如何能够成为解决秘密给药伦理挑战、尊重患者自主权并符合个人康复原则的重要工具。长效注射用抗精神病药物为精神分裂症的秘密给药提供了一种有效且符合伦理的替代方案。这种方法可以加强治疗联盟,增强患者自主权,并导致临床症状和现实世界功能的有意义改善,在具有挑战性的社会文化背景下提供了一个有价值的解决方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23c5/12419130/c9c6c883fc04/cureus-0017-00000091904-i01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验